XTL Biopharmaceuticals
XTLB
5 hedge funds and large institutions have $194K invested in XTL Biopharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
155% more capital invested
Capital invested by funds: $76K → $194K (+$118K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more funds holding
Funds holding: 4 → 5 (+1)
0% more ownership
Funds ownership: 0% → 0.01% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$76.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$32.5K |
| 3 |
Morgan Stanley
New York
|
+$8.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$818 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $75K | +$76.3K | +10,170 | New |
|
2
Invesco
Atlanta,
Georgia
| $48K | – | – | – |
|
|
3
Morgan Stanley
New York
| $37K | +$8.07K | +1,075 | +27% |
|
|
4
Citadel Advisors
Miami,
Florida
| $33K | +$32.5K | +4,328 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $1K | -$818 | -109 | -39% |
|
|
6
Bank of America
Charlotte,
North Carolina
| – | -$2K | -250 | Closed |
|
XTLB Hedge Fund Activity: Q2 2018 in Review
5 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2018, worth a combined $194K — up 155% from $76K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new XTLB positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $76.3K. The largest seller was Bank of America, exiting entirely with an estimated $2K sold.
- 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2018, up from 4 in Q1 2018.
- Funds reported $194K of XTL Biopharmaceuticals stock for Q2 2018, up 155% quarter-over-quarter.
- 2 funds opened new XTL Biopharmaceuticals positions in Q2 2018 and 1 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q2 2018 was Susquehanna International Group, an estimated $76.3K added.
- The largest XTL Biopharmaceuticals seller in Q2 2018 was Bank of America, an estimated $2K sold.
Based on aggregated 13F filings for Q2 2018.